The reason for PCSK-9 inhibitor therapy (Evolocumab: 140 mg every two weeks n = 8; Alirocumab: 75 mg every two weeks n = 2) was statin intolerance (n = 6) or residual hypercholesterolaemia despite statin therapy (n = 4) (Table 1). This evidence concerns the gene PCSK9 and Hypercholesterolemia.